FGF R2 (IIIb)

FGF R2 (IIIb) Overview

English NameFibroblast growth factor receptor 2Approved Drugs9
Drugs in Clinical Trials30Target SynonymEC:2.7.10.1,EC 2.7.10,BEK,K-sam,KGFR,FGFR2,Fibroblast Growth Factor Receptor 2,Keratinocyte Growth Factor Receptor,Bacteria-Expressed Kinase,Protein Tyrosine Kinase, Receptor Like 14,BEK Fibroblast Growth Factor Receptor,Craniofacial Dysostosis 1,Jackson-Weiss Syndrome,Pfeiffer Syndrome,Crouzon Syndrome,CD332 Antigen,EC 2.7.10.1,FGFR-2,BFR-1,CD332,BBDS,CEK3,ECT1,TK14,TK25,CFD1,KSAM,JWS,Receptor, Fibroblast Growth Factor, Type 2
Highest Development StageApproved
English NameFibroblast growth factor receptor 2
Target SynonymEC:2.7.10.1,EC 2.7.10,BEK,K-sam,KGFR,FGFR2,Fibroblast Growth Factor Receptor 2,Keratinocyte Growth Factor Receptor,Bacteria-Expressed Kinase,Protein Tyrosine Kinase, Receptor Like 14,BEK Fibroblast Growth Factor Receptor,Craniofacial Dysostosis 1,Jackson-Weiss Syndrome,Pfeiffer Syndrome,Crouzon Syndrome,CD332 Antigen,EC 2.7.10.1,FGFR-2,BFR-1,CD332,BBDS,CEK3,ECT1,TK14,TK25,CFD1,KSAM,JWS,Receptor, Fibroblast Growth Factor, Type 2
Approved Drugs9
Drugs in Clinical Trials30
Highest Development StageApproved

FGF R2 (IIIb) Product List

  • Product Category

    Protein (4)Cell (1)

  • Product Status

    Launched (5)

  • Species

    Human (3)Mouse (1)Cynomolgus (1)

  • Tag

    His Tag (3)Fc Tag (1)- (1)

  • Conjugate

    Unconjugated (4)- (1)

FGF R2 (IIIb) Background

Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.

FGF R2 (IIIb) Synonyms

FGF R2 (IIIb),FGFR2B,FGFR2

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
BemarituzumabFPA-144Phase 3 ClinicalFive Prime Therapeutics IncSolid tumours; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms
Details
RogaratinibBAY-1163877Phase 3 ClinicalBayer AGSolid tumours; Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Breast Neoplasms; Sarcoma; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung
Details
InfigratinibBGJ-398; NVP-BGJ398; BBP-831; BGJ-398 phosphatePhase 3 ClinicalNovartis Pharma AgNasopharyngeal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Glioma; Oropharyngeal Neoplasms; Gastrointestinal Stromal Tumors; Breast Neoplasms; Cholangiocarcinoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Glioblastoma; Papillomavirus Infections; Biliary Tract Neoplasms; Achondroplasia; Colonic Neoplasms; Pancreatic Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Hematologic Neoplasms; Solid tumours
Details
SC-0011SC-0011Phase 3 ClinicalShijiazhuang Zhikang Hongren New Drug Development Co LtdSolid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
ZoligratinibCH-5183284; FF-284; Debio-1347Phase 2 ClinicalChugai Pharmaceutical Co LtdSolid tumours; Breast Neoplasms
Details
AUR-109ODM-203; AUR-109Phase 2 ClinicalOrion CorpOvarian Neoplasms; Liver Neoplasms; Kidney Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms
Details
LucitanibS-80881; AL-3810; CO-3810; E-3810; S-80881-2Phase 2 ClinicalAdvenchen Laboratories Nanjing LtdSolid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Genital Neoplasms, Female; Colorectal Neoplasms; Thymus Neoplasms; Lung Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular
Details
FexagratinibAZD4547; AZD-4547; ABSK-091; ABSK091Phase 2 ClinicalAstrazeneca PlcLymphoma; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Glioma; Uterine Neoplasms; Urinary Bladder Neoplasms; Thyroid Neoplasms; Endometrial Neoplasms; Metastatic breast cancer; Melanoma; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases; Adenocarcinoma; Uterine Cervical Neoplasms; Rectal Neoplasms; Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Stomach Neoplasms; Gastrointestinal Diseases; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Liver Neoplasms; Carcinoma, Renal Cell; Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Skin Neoplasms
Details
DerazantinibARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087Phase 2 ClinicalArqule IncSolid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular
Details
HH1853D-185; 3-D185; HH-185; 3D185Phase 2 ClinicalShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon IncSolid tumours; Cholangiocarcinoma
Details
3HP-28273HP-2827; 3HP2827Phase 2 Clinical3H (Suzhou) Pharmaceuticals Co LtdSolid tumours; Neoplasms
Details
CGT-4859CGT4859; CGT-4859Phase 2 ClinicalCogent Biosciences IncSolid tumours; Neoplasms; Cholangiocarcinoma
Details
FanregratinibHMPL-453Phase 2 ClinicalHutchison Medipharma LtdSolid tumours; Biliary Tract Neoplasms; Neoplasms, Mesothelial; Mesothelioma; Cholangiocarcinoma
Details
ABSK-061ABSK061Phase 2 ClinicalABbisko Therapeutics Co LtdSolid tumours; Esophageal Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung
Details
LirafugratinibRLY-4008Phase 2 ClinicalRelay Therapeutics IncSolid tumours; Translocation, Genetic; Cholangiocarcinoma
Details
PZH-2111PZH2111; PZH-2111Phase 2 ClinicalZhangzhou Pientzehuang Pharmaceutical Co LtdSolid tumours; Cholangiocarcinoma
Details
GunagratinibICP-192Phase 2 ClinicalBeijing Tiancheng Pharmaceutical Technology Co LtdSolid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms
Details
BPI-17509BPI-17509Phase 1 ClinicalBetta Pharmaceuticals Co LtdSolid tumours
Details
nintedanib (Avalyn Pharma)Phase 1 ClinicalAvalyn Pharma IncIdiopathic Pulmonary Fibrosis; Pulmonary Fibrosis
Details
TYRA-200TYRA200; TYRA-200Phase 1 ClinicalTyra Biosciences IncSolid tumours; Biliary Tract Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms
Details
ResigratinibKIN-3248; KIN-003Phase 1 ClinicalKinnate Biopharma IncSolid tumours; Carcinoma, Transitional Cell; Neoplasms; Cholangiocarcinoma
Details
KNT-0916KNT0916; KNT-0916Phase 1 ClinicalGuangzhou Kentai Biopharmaceutical Technology Co LtdSolid tumours; Neoplasm Metastasis
Details
BG-C137BG-C137Phase 1 ClinicalBeOne Medicines LtdSolid tumours; Gastrointestinal Neoplasms
Details
ACE-16229210ACE-16229210; ACE16229210Phase 1 ClinicalAcerand Therapeutics (Shanghai) LtdSolid tumours
Details
MNKD-201MNKD-201; MKND-201Phase 1 ClinicalMannKind CorpIdiopathic Pulmonary Fibrosis
Details
Inhaled Nintedanib – dry powder (Avalyn Pharma)AP02; AP 02 DP; AP-02; AP02-DPPhase 1 ClinicalAvalyn Pharma IncIdiopathic Pulmonary Fibrosis; Respiratory Tract Diseases; Lung Diseases, Interstitial; Pulmonary Fibrosis
Details
TT-00434TT-00434Phase 1 ClinicalTransThera Sciences (Nanjing) IncSolid tumours; Urinary Bladder Neoplasms
Details
ABSK-121ABSK121-NX; ABSK121Phase 1 ClinicalABbisko Therapeutics Co LtdSolid tumours
Details
LY-2874455LY-2874455Phase 1 ClinicalEli Lilly And CompanyNeoplasms; Leukemia, Myeloid, Acute
Details
CPL-304110CPL-304110; CPL-304-110Phase 1 ClinicalCelon Pharma SaStomach Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Sarcoma; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Anlotinib DihydrochlorideAL-3818ApprovedAdvenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd福可维Mainland ChinaCarcinoma, Non-Small-Cell LungJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd2018-05-08Sarcoma, Alveolar Soft Part; Peritoneal Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Insufficiency; Bone Neoplasms; Endometrial Neoplasms; Gallbladder Neoplasms; Fallopian Tube Neoplasms; Thyroid Neoplasms; Medullary thyroid cancer (MTC); Glioma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Osteoma; Gastroenteropancreatic neuroendocrine tumor; Small Cell Lung Carcinoma; Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Leiomyosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Neuroendocrine Tumors; Sarcoma, Synovial; Lung Diseases, Interstitial; Liver Diseases; Sarcoma; Bile Duct Diseases; Nasopharyngeal Carcinoma
Details
Lenvatinib MesylateMK-7902; ER-203492-00; E-7080ApprovedEisai Co LtdKisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛United StatesThyroid NeoplasmsEisai Inc2015-02-13Neuroendocrine Tumors; Paraganglioma; Thyroid Cancer, Papillary; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Neoplasms; Renal Insufficiency; Pheochromocytoma; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms
Details
RegorafenibDAST; BAY-73-4506ApprovedBayer AGStivarga, ResihanceUnited StatesColorectal NeoplasmsBayer Healthcare Pharmaceuticals Inc2012-09-27Leukemia, Myeloid, Acute; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Osteosarcoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Adenocarcinoma; Somatostatinoma; Gastrointestinal Neoplasms; Melanoma; Meningioma; Neoplasms; Solid tumours; Liver Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Insulinoma; Carcinoma, Islet Cell; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Gastrinoma; Sarcoma
Details
Nintedanib EsylateBIBF-1120ApprovedC.H. Boehringer Sohn Ag & Co. KgOfev, VargatefUnited StatesIdiopathic Pulmonary FibrosisBoehringer Ingelheim Gmbh2014-10-15Astrocytoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Silicosis; Genital Neoplasms, Female; Hepatic Insufficiency; Oligodendroglioma; Gliosarcoma; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Appendiceal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Glioblastoma; Solid tumours; Telangiectasia, Hereditary Hemorrhagic; Carcinoma, Renal Cell; Endometrial Stromal Tumors; Carcinoid Tumor; Radiation Pneumonitis; Esophageal Neoplasms; Rejection of lung transplantation; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Colonic Neoplasms; Scleroderma, Systemic; Lung Diseases, Interstitial; Pulmonary Fibrosis; Mesothelioma; Multiple Myeloma; Asbestosis; Neuroendocrine Tumors
Details
FutibatinibTAS-120ApprovedTaiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co LtdLYTGOBIUnited StatesCholangiocarcinomaTaiho Oncology Inc2022-09-30Central Nervous System Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Endometrial Neoplasms; Lymphoma; Metastatic breast cancer; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Esophageal Neoplasms; Carcinoma; Stomach Neoplasms; Bone Marrow Neoplasms; Solid tumours
Details
SelpercatinibARRY-192; Ret-IN-1; LOXO-292; LY-3527723ApprovedArray BiopharmaRetevmo, RetsevmoUnited StatesMedullary thyroid cancer (MTC); Carcinoma, Non-Small-Cell Lung; Thyroid NeoplasmsLoxo Oncology Inc2020-05-08Medullary thyroid cancer (MTC); Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Thyroid Cancer, Papillary; Carcinoma, Non-Small-Cell Lung; Glioma; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Thyroid Neoplasms; Hepatic Insufficiency; Neuroblastoma; Histiocytosis, Langerhans-Cell; Sarcoma, Ewing; Osteosarcoma; Fibrosarcoma; Sarcoma; Myofibromatosis; Wilms Tumor; Neoplasms; Thyroid Carcinoma, Anaplastic; Colonic Neoplasms; Hepatoblastoma; Rhabdoid Tumor; Renal Insufficiency; Medulloblastoma; Ependymoma; Rhabdomyosarcoma; Hematologic Neoplasms; Solid tumours
Details
PemigatinibINCB-054828; INCB-54828; IBI-375ApprovedIncyte CorpPemazyre, 伯坦, 达伯坦United StatesCholangiocarcinomaIncyte Corp2020-04-17Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Lymphoma, Non-Hodgkin; Glioma; Endometrial Neoplasms; Lung Neoplasms; Lymphoma; Urologic Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Colitis, Ulcerative; Translocation, Genetic; Breast Neoplasms; Biliary Tract Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Myeloproliferative Disorders; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; Solid tumours; Bone Marrow Neoplasms
Details
TasurgratinibE-7090ApprovedEisai Co LtdTASFYGOJapanBiliary Tract NeoplasmsEisai Co Ltd2024-09-24Biliary Tract Neoplasms; Solid tumours; Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency
Details
Erdafitinib890E37NHMV; G-024; JNJ-493; JNJ-42756493; TAR-210ApprovedAstex Pharmaceuticals IncBalversa, 博珂United StatesCarcinoma, Transitional CellJanssen Biotech Inc2019-04-12Glioma; Osteosarcoma; Sarcoma, Ewing; Neuroblastoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Histiocytic Sarcoma; Hepatic Insufficiency; Lymphoma; Lymphoma, Non-Hodgkin; Sarcoma; Carcinoma, Squamous Cell; Metastatic breast cancer; Carcinoma, Neuroendocrine; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors, Primitive, Peripheral; Xanthogranuloma, Juvenile; Adenocarcinoma; Hepatoblastoma; Ependymoma; Medulloblastoma; Rhabdomyosarcoma; Hematologic Neoplasms; Bone metastases; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Rhabdoid Tumor; Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Ganglioglioma; Wilms Tumor; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Histiocytosis, Langerhans-Cell
Details

Product Reviews

  • W***A2025-11-07
    0People Like
    We used ACROBiosystems protein for experiments to detect the affinity constant after our antibody Fc end binds with it. The experimental data showed good effects. We conducted 8 experiments and the affinity is strong, the KD values of each experiment are within the same order of magnitude, and are comparable to the positive control group. The accuracy of the experimental results has also improved a lot.
  • Overview
  • Product List
  • Marketed Drug Information
  • Product Reviews
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland